Search research articles
Contact Us
Filters
Showing results (171-180 of 252) with videos related to
Page
of 26
Sort By:
Blood Advances
|
July 24, 2019
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion
Michael R Bishop, Richard T Maziarz, Edmund K Waller, et al.
Hemasphere
|
August 20, 2025
Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients
Paul J Bröckelmann, Boris Böll, Daniel Molin, et al.
Leukemia
|
September 29, 2021
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
Maria A Garcia-Marquez, Martin Thelen, Sarah Reinke, et al.
Infection
|
February 19, 2022
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma
Anne Sophie Jacob, Helen Kaul, Michael Fuchs, et al.
British Journal of Haematology
|
September 14, 2021
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
Elena Gerhard-Hartmann, Helen Goergen, Paul J Bröckelmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2010
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
Andreas Josting, Horst Müller, Peter Borchmann, et al.
Leukemia & Lymphoma
|
July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
Haematologica
|
February 26, 2026
Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis
Hishan Tharmaseelan, Lisa M Sgonina, Ina Bühnen, et al.
Page
of 26
Search research articles
Search
Showing results (171-180 of 252) with videos related to
Sort By:
Page
of 26
Blood Advances
|
July 24, 2019
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion
Michael R Bishop, Richard T Maziarz, Edmund K Waller, et al.
Hemasphere
|
August 20, 2025
Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients
Paul J Bröckelmann, Boris Böll, Daniel Molin, et al.
Leukemia
|
September 29, 2021
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
Maria A Garcia-Marquez, Martin Thelen, Sarah Reinke, et al.
Infection
|
February 19, 2022
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma
Anne Sophie Jacob, Helen Kaul, Michael Fuchs, et al.
British Journal of Haematology
|
September 14, 2021
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
Elena Gerhard-Hartmann, Helen Goergen, Paul J Bröckelmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2010
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
Andreas Josting, Horst Müller, Peter Borchmann, et al.
Leukemia & Lymphoma
|
July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
Haematologica
|
February 26, 2026
Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis
Hishan Tharmaseelan, Lisa M Sgonina, Ina Bühnen, et al.
Page
of 26